A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Registration Number
- NCT06136559
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1200
The main inclusion criteria include but are not limited to the following:
- Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy.
- Has at least 1 marker of disease burden.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.
- Has the ability to swallow and retain oral medication.
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.
- Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.
The main exclusion criteria include but are not limited to the following:
- Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.
- Has gastrointestinal (GI) dysfunction that may affect drug absorption.
- Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.
- Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
- Has clinically significant cardiovascular disease.
- Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients.
- Has history of severe bleeding disorder.
- Has history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
- Has received any systemic anticancer therapy for CLL/SLL.
- Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.
- Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
- Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
- Has active infection requiring systemic therapy.
- Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Ibrutinib/Acalabrutinib Acalabrutinib Participants will receive investigator's choice of ibrutinib or acalabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met. Ibrutinib/Acalabrutinib Ibrutinib Participants will receive investigator's choice of ibrutinib or acalabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met. Nemtabrutinib Nemtabrutinib Participants will receive nemtabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICR Up to ~104 months PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD is evaluated per iwCLL Criteria 2018 as assessed by BICR.
Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR) Up to ~33 months ORR is defined as the percentage of participants with complete response (CR), complete response with an incomplete recovery of the participant's bone marrow (CRi), nodular partial response (nPR), or partial response (PR), per iwCLL Criteria 2018 as assessed by BICR.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) Up to ~104 months OS is defined as the time from randomization to death due to any cause.
Duration of Response (DOR) per iwCLL Criteria 2018 as assessed by BICR Up to ~104 months For participants who demonstrate a complete response (CR), complete response with an incomplete recovery of the participant's bone marrow (CRi), nodular partial response (nPR), or partial response (PR) per iwCLL Criteria 2018 as assessed by BICR, DOR is defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first.
Number of Participants Who Experience One or More Adverse Events (AEs) Up to ~104 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Number of Participants Who Discontinue Study Treatment Due to an AE Up to ~104 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Trial Locations
- Locations (172)
USA Mitchell Cancer Institute ( Site 0014)
🇺🇸Mobile, Alabama, United States
Florida Cancer Specialists - East ( Site 7002)
🇺🇸West Palm Beach, Florida, United States
Arizona Oncology Associates - NAHOA ( Site 8007)
🇺🇸Prescott, Arizona, United States
Alta Bates Summit Medical Center ( Site 0004)
🇺🇸Berkeley, California, United States
Moores Cancer Center ( Site 0003)
🇺🇸La Jolla, California, United States
Saint Joseph Hospital ( Site 0026)
🇺🇸Denver, Colorado, United States
Lutheran Medical Center ( Site 0027)
🇺🇸Golden, Colorado, United States
Intermountain Health St. Mary's Regional Hospital ( Site 0025)
🇺🇸Grand Junction, Colorado, United States
Florida Cancer Specialists - South ( Site 7001)
🇺🇸Fort Myers, Florida, United States
Eastern CT Hematology & Oncology Associates ( Site 0033)
🇺🇸Norwich, Connecticut, United States
Parkview Research Center at Parkview Regional Medical Center ( Site 0002)
🇺🇸Fort Wayne, Indiana, United States
University of Iowa-Holden Comprehensive Cancer Center ( Site 0017)
🇺🇸Iowa City, Iowa, United States
Saint Elizabeth Healthcare ( Site 0041)
🇺🇸Edgewood, Kentucky, United States
Roswell Park Cancer Institute ( Site 0023)
🇺🇸Buffalo, New York, United States
Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)
🇺🇸Grand Rapids, Michigan, United States
Summit Medical Group Cancer Center ( Site 0007)
🇺🇸Florham Park, New Jersey, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016)
🇺🇸Hackensack, New Jersey, United States
Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002)
🇺🇸Broomall, Pennsylvania, United States
Cancer Care Associates Of York ( Site 0005)
🇺🇸York, Pennsylvania, United States
Texas Oncology - Central/South Texas ( Site 8008)
🇺🇸Austin, Texas, United States
Texas Oncology - San Antonio ( Site 8006)
🇺🇸San Antonio, Texas, United States
Texas Oncology - Northeast Texas ( Site 8012)
🇺🇸Tyler, Texas, United States
Inova Schar Cancer Institute ( Site 0015)
🇺🇸Fairfax, Virginia, United States
Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010)
🇺🇸Spokane, Washington, United States
University Hospital and UW Health Clinics ( Site 0006)
🇺🇸Madison, Wisconsin, United States
Royal North Shore Hospital ( Site 2806)
🇦🇺St Leonards, New South Wales, Australia
AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0205)
🇧🇪Mechelen, Antwerpen, Belgium
UZ Leuven-Hematology ( Site 0200)
🇧🇪Leuven, Vlaams-Brabant, Belgium
Hospital 9 De Julho ( Site 2206)
🇧🇷São Paulo, Sao Paulo, Brazil
Instituto Nacional de Câncer - INCA ( Site 2201)
🇧🇷Rio de Janeiro, Brazil
Hospital Paulistano-Americas Oncologia ( Site 2202)
🇧🇷Sao Paulo, Brazil
BC Cancer Victoria ( Site 0109)
🇨🇦Victoria, British Columbia, Canada
William Osler Health System ( Site 0103)
🇨🇦Brampton, Ontario, Canada
The Ottawa Hospital - General Campus ( Site 0102)
🇨🇦Ottawa, Ontario, Canada
McGill University Health Centre ( Site 0106)
🇨🇦Montréal, Quebec, Canada
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski ( Site 0100)
🇨🇦Rimouski, Quebec, Canada
Bradfordhill-Clinical Area ( Site 2310)
🇨🇱Santiago., Region M. De Santiago, Chile
FALP-UIDO ( Site 2300)
🇨🇱Santiago, Region M. De Santiago, Chile
Clínica Alemana de Santiago-Unidad de Investigaciones ( Site 2306)
🇨🇱Santiago, Region M. De Santiago, Chile
Anhui Provincial Cancer Hospital ( Site 2001)
🇨🇳Hefei, Anhui, China
Peking University First Hospital ( Site 2022)
🇨🇳Beijing, Beijing, China
Peking University Third Hospital-Hematology ( Site 2011)
🇨🇳Beijing, Beijing, China
Chongqing University Cancer Hospital ( Site 2041)
🇨🇳Chongqing, Chongqing, China
Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 2006)
🇨🇳Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center ( Site 2028)
🇨🇳Guangzhou, Guangdong, China
Liuzhou People's Hospital ( Site 2029)
🇨🇳Liuzhou, Guangxi, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 2004)
🇨🇳Nanning, Guangxi, China
The Affiliated Hospital of Guizhou Medical University ( Site 2024)
🇨🇳Guiyang, Guizhou, China
Hainan General Hospital ( Site 2018)
🇨🇳Haikou, Hainan, China
Henan Cancer Hospital-hematology department ( Site 2025)
🇨🇳Zhengzhou, Henan, China
Tongji Hospital Affiliated to Tongji Medical College of HUST ( Site 2016)
🇨🇳Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2015)
🇨🇳Wuhan, Hubei, China
Hunan Cancer Hospital ( Site 2020)
🇨🇳Changsha, Hunan, China
The Second Xiangya Hospital of Central South University ( Site 2010)
🇨🇳Changsha, Hunan, China
Jiangsu Province Hospital ( Site 2000)
🇨🇳Nanjing, Jiangsu, China
The First Affliated Hospital of Suzhou University ( Site 2027)
🇨🇳Suzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical College ( Site 2013)
🇨🇳Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University ( Site 2023)
🇨🇳Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital ( Site 2009)
🇨🇳Nanchang, Jiangxi, China
The First Hospital of Jilin University-Hematology ( Site 2030)
🇨🇳Changchun, Jilin, China
Shaanxi provincial people's hospital ( Site 2012)
🇨🇳Xian, Shaanxi, China
Shandong Cancer Hospital ( Site 2003)
🇨🇳Jinan, Shandong, China
Shanxi Cancer Hospital ( Site 2033)
🇨🇳Taiyuan, Shanxi, China
West China Hospital, Sichuan University-Head and Neck Oncology ( Site 2026)
🇨🇳Cheng Du, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 2019)
🇨🇳Tianjin, Tianjin, China
Institute of hematology&blood disease hospital-Lymphoma ( Site 2005)
🇨🇳Tianjin, Tianjin, China
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2014)
🇨🇳Urumqi, Xinjiang, China
The first Affiliated Hospital, Zhejiang University School of Medicine-Hematology ( Site 2002)
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 2017)
🇨🇳Hangzhou, Zhejiang, China
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 2405)
🇨🇴Valledupar, Cesar, Colombia
IMAT S.A.S ( Site 2401)
🇨🇴Monteria, Cordoba, Colombia
Fundacion Valle del Lili- CIC-Oncology CIC ( Site 2402)
🇨🇴Cali, Valle Del Cauca, Colombia
Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0301)
🇨🇿Hradec Kralove, Czechia
Fakultni nemocnice Olomouc ( Site 0303)
🇨🇿Olomouc, Czechia
Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302)
🇨🇿Praha 2, Czechia
Aalborg Universitetshospital, Syd ( Site 0403)
🇩🇰Aalborg, Nordjylland, Denmark
Roskilde Sygehus-Department of Hematology ( Site 0402)
🇩🇰Roskilde, Sjaelland, Denmark
Kliniken Maria Hilf ( Site 0603)
🇩🇪Mönchengladbach, Nordrhein-Westfalen, Germany
InVO Institut für Versorgungsforschung in der Onkologie ( Site 0606)
🇩🇪Koblenz, Rheinland-Pfalz, Germany
Odense Universitetshospital-Department of Hematology ( Site 0401)
🇩🇰Odense C, Syddanmark, Denmark
Universitaetsklinikum Ulm. ( Site 0601)
🇩🇪Ulm, Baden-Wurttemberg, Germany
Universitätsklinikum Halle ( Site 0604)
🇩🇪Halle, Sachsen-Anhalt, Germany
Onkologische Schwerpunktpraxis Kurfuerstendamm ( Site 0600)
🇩🇪Berlin, Germany
University Hospital of Alexandroupolis ( Site 0701)
🇬🇷Alexandroupolis, Anatoliki Makedonia Kai Thraki, Greece
Evangelismos General Hospital of Athens ( Site 0700)
🇬🇷Athens, Attiki, Greece
VK&K Studien GbR ( Site 0607)
🇩🇪Landshut, Bayern, Germany
General Hospital of Athens "Laiko" ( Site 0704)
🇬🇷Athens, Attiki, Greece
University Hospital of Ioannina ( Site 0702)
🇬🇷Ioannina, Greece
Queen Mary Hospital ( Site 3300)
🇭🇰Hong Kong, Hong Kong
Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 1503)
🇮🇱Haifa, Israel
Bnai Zion Medical Center ( Site 1505)
🇮🇱Haifa, Israel
Hadassah Medical Center-Hemato-Oncology ( Site 1500)
🇮🇱Jerusalem, Israel
Rabin Medical Center ( Site 1504)
🇮🇱Petah Tikva, Israel
Sheba Medical Center-Hemato Oncology ( Site 1501)
🇮🇱Ramat Gan, Israel
Yitzhak Shamir Medical Center. ( Site 1506)
🇮🇱Zerifin, Israel
Nagoya University Hospital ( Site 1907)
🇯🇵Nagoya, Aichi, Japan
Gunma University Hospital ( Site 1903)
🇯🇵Maebashi, Gunma, Japan
Hokkaido University Hospital ( Site 1900)
🇯🇵Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital ( Site 1910)
🇯🇵Kobe, Hyogo, Japan
Tohoku University Hospital ( Site 1901)
🇯🇵Sendai, Miyagi, Japan
Kindai University Hospital ( Site 1909)
🇯🇵Sayama, Osaka, Japan
Shimane University Hospital ( Site 1911)
🇯🇵Izumo, Shimane, Japan
Cancer Institute Hospital of JFCR ( Site 1906)
🇯🇵Koto, Tokyo, Japan
Chiba Cancer Center ( Site 1905)
🇯🇵Chiba, Japan
Kyushu University Hospital ( Site 1914)
🇯🇵Fukuoka, Japan
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 1913)
🇯🇵Hiroshima, Japan
Okayama University Hospital ( Site 1912)
🇯🇵Okayama, Japan
Japanese Red Cross Osaka Hospital ( Site 1908)
🇯🇵Osaka, Japan
Yamagata University Hospital ( Site 1902)
🇯🇵Yamagata, Japan
University Malaya Medical Centre ( Site 1604)
🇲🇾Lembah Pantai, Kuala Lumpur, Malaysia
Hospital Pulau Pinang ( Site 1602)
🇲🇾George Town, Pulau Pinang, Malaysia
Queen Elizabeth Hospital ( Site 1603)
🇲🇾Kota Kinabalu, Sabah, Malaysia
Centro de Infusion Superare ( Site 2602)
🇲🇽Ciudad de México, Distrito Federal, Mexico
Health Pharma Professional Research S.A. de C.V: ( Site 2608)
🇲🇽Ciudad de México, Distrito Federal, Mexico
Waikato Hospital-Haematology ( Site 3202)
🇳🇿Hamilton, Waikato, New Zealand
North Shore Hospital-Department of Haematology ( Site 3200)
🇳🇿Auckland, New Zealand
Aotearoa Clinical Trials ( Site 3201)
🇳🇿Auckland, New Zealand
Akershus Universitetssykehus ( Site 0902)
🇳🇴Lørenskog, Akershus, Norway
Oslo Universitetssykehus Rikshospitalet-Avdeling for blodsykdommer ( Site 0901)
🇳🇴Oslo, Norway
Centro Medico Monte Carmelo-Oncology ( Site 2706)
🇵🇪Arequipa, Ariqipa, Peru
Clínica Anglo Americana ( Site 2701)
🇵🇪Lima, Peru
Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie-Oddział Hematoonkologii, Transplantacji Szp ( Site 1006)
🇵🇱Lublin, Lubelskie, Poland
Pratia MCM Krakow ( Site 1007)
🇵🇱Krakow, Malopolskie, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1004)
🇵🇱Warszawa, Mazowieckie, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 1011)
🇵🇱Gdansk, Pomorskie, Poland
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oddział Hematologii i Transplantacji ( Site 1013)
🇵🇱Słupsk, Pomorskie, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1000)
🇵🇱Gliwice, Slaskie, Poland
Pratia Onkologia Katowice ( Site 1009)
🇵🇱Katowice, Slaskie, Poland
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1005)
🇵🇱Olsztyn, Warminsko-mazurskie, Poland
Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3103)
🇵🇹Lisbon, Lisboa, Portugal
Champalimaud Foundation ( Site 3102)
🇵🇹Lisbon, Lisboa, Portugal
Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 3107)
🇵🇹Vila Nova de Gaia, Porto, Portugal
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3104)
🇵🇹Lisboa, Portugal
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3106)
🇵🇹Lisboa, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3100)
🇵🇹Porto, Portugal
Netcare Pretoria East Hospital-Alberts Cellular Therapy ( Site 1101)
🇿🇦Centurion, Gauteng, South Africa
Wits Clinical Research ( Site 1102)
🇿🇦Johannesburg, Gauteng, South Africa
Groote Schuur Hospital-Clinical Haematology ( Site 1100)
🇿🇦Cape Town, Western Cape, South Africa
Haemalife ( Site 1105)
🇿🇦Kuilsriver, Western Cape, South Africa
Constantiaberg Haematology ( Site 1106)
🇿🇦Plumstead, Western Cape, South Africa
Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 1207)
🇪🇸L'Hospitalet Del Llobregat, Barcelona, Spain
HOSPITAL CLÍNIC DE BARCELONA ( Site 1202)
🇪🇸Barcelona, Cataluna, Spain
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 1208)
🇪🇸Majadahonda, Madrid, Comunidad De, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1209)
🇪🇸Pozuelo de Alarcon, Madrid, Spain
hospital universitario de canarias ( Site 1205)
🇪🇸La Laguna, Santa Cruz De Tenerife, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1206)
🇪🇸Barcelona, Spain
Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 1201)
🇪🇸Salamanca, Spain
Karolinska Universitetssjukhuset Solna ( Site 1302)
🇸🇪Stockholm, Stockholms Lan, Sweden
Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 1702)
🇨🇳Kaohsiung, Taiwan
National Cheng Kung University Hospital ( Site 1700)
🇨🇳Tainan, Taiwan
National Taiwan University Hospital ( Site 1701)
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 1703)
🇨🇳Taoyuan, Taiwan
Maharaj Nakorn Chiang Mai Hospital ( Site 1800)
🇹🇭Muang, Chiang Mai, Thailand
Chulalongkorn University ( Site 1802)
🇹🇭Bangkok, Krung Thep Maha Nakhon, Thailand
Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 1801)
🇹🇭Bangkok, Krung Thep Maha Nakhon, Thailand
Naresuan University Hospital ( Site 1804)
🇹🇭Muang, Phitsanulok, Thailand
Songklanagarind hospital ( Site 1803)
🇹🇭HatYai, Songkhla, Thailand
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 1401)
🇹🇷Ankara, Turkey
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1407)
🇹🇷Ankara, Turkey
Antalya Egitim ve Arastırma Hastanesi ( Site 1409)
🇹🇷Antalya, Turkey
Trakya University-Balkan Onkoloji Hastanesi ( Site 1403)
🇹🇷Edirne, Turkey
Marmara Universitesi Pendik Egitim Arastirma Hastanesi ( Site 1408)
🇹🇷Istanbul, Turkey
Ege Universitesi Hastanesi ( Site 1404)
🇹🇷İzmir, Turkey
Ondokuz Mays Üniversitesi ( Site 1410)
🇹🇷Samsun, Turkey
Southmead Hospital ( Site 3010)
🇬🇧Bristol, Bristol, City Of, United Kingdom
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3006)
🇬🇧London, London, City Of, United Kingdom
The Churchill Hospital ( Site 3007)
🇬🇧Oxford, Oxfordshire, United Kingdom
GenesisCare - Cambridge ( Site 3001)
🇬🇧Newmarket, Suffolk, United Kingdom
GenesisCare - Windsor ( Site 3002)
🇬🇧Windsor, Windsor And Maidenhead, United Kingdom
Barnet Hospital ( Site 3005)
🇬🇧Barnet, United Kingdom
St James's University Hospital ( Site 3004)
🇬🇧Leeds, United Kingdom
City Hospital, Nottingham University Hospitals NHS Trust ( Site 3003)
🇬🇧Nottingham, United Kingdom